Sol-Gel Technologies ROA 2016-2026 | SLGL
Current and historical return on assets (ROA) values for Sol-Gel Technologies (SLGL) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Sol-Gel Technologies ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $0.00B | $0.04B | -2.45% |
| 2025-12-31 | $-0.01B | $0.03B | -18.32% |
| 2025-09-30 | $-0.01B | $0.03B | -26.28% |
| 2025-06-30 | $0.00B | $0.04B | -8.28% |
| 2025-03-31 | $-0.01B | $0.04B | -35.14% |
| 2024-12-31 | $-0.01B | $0.04B | -24.84% |
| 2024-09-30 | $-0.01B | $0.04B | -21.18% |
| 2024-06-30 | $-0.02B | $0.04B | -33.90% |
| 2024-03-31 | $-0.02B | $0.05B | -48.42% |
| 2023-12-31 | $-0.03B | $0.05B | -56.28% |
| 2023-09-30 | $-0.03B | $0.05B | -57.71% |
| 2023-06-30 | $-0.03B | $0.05B | -51.49% |
| 2023-03-31 | $-0.02B | $0.05B | -39.60% |
| 2022-12-31 | $-0.02B | $0.05B | -28.71% |
| 2022-09-30 | $0.01B | $0.06B | 8.66% |
| 2022-06-30 | $0.01B | $0.06B | 15.45% |
| 2022-03-31 | $0.00B | $0.06B | 1.79% |
| 2021-12-31 | $0.00B | $0.06B | 5.41% |
| 2021-09-30 | $-0.02B | $0.05B | -32.08% |
| 2021-06-30 | $-0.03B | $0.06B | -48.00% |
| 2021-03-31 | $-0.03B | $0.06B | -40.94% |
| 2020-12-31 | $-0.03B | $0.07B | -41.88% |
| 2020-09-30 | $-0.03B | $0.07B | -43.01% |
| 2020-06-30 | $-0.03B | $0.07B | -39.86% |
| 2020-03-31 | $-0.03B | $0.07B | -38.66% |
| 2019-12-31 | $-0.03B | $0.07B | -38.46% |
| 2019-09-30 | $-0.03B | $0.07B | -44.61% |
| 2019-06-30 | $-0.03B | $0.07B | -43.97% |
| 2019-03-31 | $-0.03B | $0.08B | -43.28% |
| 2018-12-31 | $-0.03B | $0.08B | -40.37% |
| 2018-03-31 | $-0.01B | $0.03B | -42.48% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.210B | $0.019B |
| Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |